Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
- Written by ACN Newswire - Press Releases
Read more //?#
.
Global Thryv voices bring a sharper lens to International Women’s Day
Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...
AI curiosity fuels new wave of employee-led innovation in Australia
Leaders across Australia are asking themselves how they can ensure their employees get the most out of AI. We recently conducted research to help an...
Is your search bar your competitor’s best salesperson?
A few weeks ago, I was watching the Super Bowl. Traditionally, those halftime ad spots are reserved for the world’s biggest, most established bran...
AIIMS Group and AdVisible merge
Two of Australia’s most established independent agencies unite, creating marketing powerhouse backed by three decades of combined experience ...
Block's layoffs are a design win. Here's why
We spend millions designing features that save users 30 seconds. Block just saved thousands of employees 40 hours a week. That's not a crisis. That's...
Why I Decided to Build a Better Way to Build Homes
Why does building a home still feel like stepping into the unknown? In an industry where costs blow out and decisions come too late, certainty has...